Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grace S Park

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Plastic and Reconstructive Surgery|December 2, 2025
OnabotulinumtoxinA for Platysma Prominence: Safety and Efficacy Results from a Phase 3 Open-Label Repeat Treatment StudyDeanne Mraz, C William Hanke, Ira Papel, et al.
Arthritis Care & Research|October 20, 2010
Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritisMichael E Weinblatt, Joan M Bathon, Joel M Kremer, et al.
Annals of the Rheumatic Diseases|May 3, 2007
Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohortVeena K Ranganath, Jeonglim Yoon, Dinesh Khanna, et al.
The Journal of Rheumatology|January 30, 2010
Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritisHaoling H Weng, Veena K Ranganath, Dinesh Khanna, et al.
Plastic and Reconstructive Surgery|April 19, 2024
Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Platysma Prominence: A Randomized Phase 2 Dose-Ranging StudyRod J Rohrich, Vince Bertucci, Steven Dayan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 15, 2023
Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized StudyQuentin M Anstee, Brent A Neuschwander-Tetri, Vincent Wai-Sun Wong, et al.
Aesthetic Surgery Journal|July 4, 2026
Treatment Satisfaction, Improvements in Jawline Definition, and Psychosocial Impact With OnabotulinumtoxinA for Platysma Prominence: Patient-Reported Outcomes From 2 Multicenter, Randomized, Placebo-Controlled Phase 3 StudiesPatricia Ogilvie, William P Coleman, Steven Dayan, et al.
Aesthetic Surgery Journal|July 14, 2026
Safety and Efficacy of TrenibotulinumtoxinE for Moderate-to-Severe Glabellar Lines: A Phase 2b, Double-Blind, Placebo-Controlled, Dose-Escalation StudyEdward Lain, Leslie Baumann, Suzanne Bruce, et al.
Arthritis and Rheumatism|September 2, 2006
Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosusXuebing Feng, Hui Wu, Jennifer M Grossman, et al.
The Journal of Rheumatology|May 4, 2005
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trialDinesh Khanna, Daniel E Furst, Philip J Clements, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Plastic and Reconstructive Surgery|December 2, 2025
OnabotulinumtoxinA for Platysma Prominence: Safety and Efficacy Results from a Phase 3 Open-Label Repeat Treatment StudyDeanne Mraz, C William Hanke, Ira Papel, et al.
Arthritis Care & Research|October 20, 2010
Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritisMichael E Weinblatt, Joan M Bathon, Joel M Kremer, et al.
Annals of the Rheumatic Diseases|May 3, 2007
Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohortVeena K Ranganath, Jeonglim Yoon, Dinesh Khanna, et al.
The Journal of Rheumatology|January 30, 2010
Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritisHaoling H Weng, Veena K Ranganath, Dinesh Khanna, et al.
Plastic and Reconstructive Surgery|April 19, 2024
Efficacy and Safety of OnabotulinumtoxinA for the Treatment of Platysma Prominence: A Randomized Phase 2 Dose-Ranging StudyRod J Rohrich, Vince Bertucci, Steven Dayan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 15, 2023
Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized StudyQuentin M Anstee, Brent A Neuschwander-Tetri, Vincent Wai-Sun Wong, et al.
Aesthetic Surgery Journal|July 4, 2026
Treatment Satisfaction, Improvements in Jawline Definition, and Psychosocial Impact With OnabotulinumtoxinA for Platysma Prominence: Patient-Reported Outcomes From 2 Multicenter, Randomized, Placebo-Controlled Phase 3 StudiesPatricia Ogilvie, William P Coleman, Steven Dayan, et al.
Aesthetic Surgery Journal|July 14, 2026
Safety and Efficacy of TrenibotulinumtoxinE for Moderate-to-Severe Glabellar Lines: A Phase 2b, Double-Blind, Placebo-Controlled, Dose-Escalation StudyEdward Lain, Leslie Baumann, Suzanne Bruce, et al.
Arthritis and Rheumatism|September 2, 2006
Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosusXuebing Feng, Hui Wu, Jennifer M Grossman, et al.
The Journal of Rheumatology|May 4, 2005
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trialDinesh Khanna, Daniel E Furst, Philip J Clements, et al.
Pageof 4